Study finds, Long-term TNF inhibitor use in Rheumatoid arthr
A study was conducted to estimate the occurrence and relative risks of first-ever incident non-cutaneous cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment began, attained age, and time on active treatment in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs).

Observational nationwide and population-based cohort study of patients with RA(n=69308), treated with TNF inhibitors or other b/tsDMARDs compared with RA patients not treated with b/tsDMARDs, and matched general population referents (n=109532) were involved.

--Based on 8633 incident cancers among RA patients, the overall relative risk of cancer with TNFi was neither increased nor did it change with time since treatment start, time on active treatment, or attained age, when compared with b/tsDMARD-naïve RA.

--For other b/tsDMARDs, no consistent signal of increased overall risks were noted, but statistically significant estimates above 1 for abatacept with 2–5 years of active treatment, for older age groups, and between several of the bDMARDs and urinary tract cancer.

TNFi, in particular, has not been related to an increased risk of cancer in general when taken long-term in clinical practice against RA. These findings are generally comforting for various b/tsDMARDs and site-specific hazards, although they contain signals that require replication.